TIGIT Gastrointestinal September 1, 2026 The SKYSCRAPER trials have been investigating dual immune checkpoint inhibition with atezolizumab and the TIGIT inhibitor tiragolumab. We recently saw…
SKYSCRAPER Lung August 11, 2026 Top Line: Is dual immune checkpoint inhibition better than durvalumab after chemoradiation for stage III NSCLC?The Study: Chemoradiation followed by…
